These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 2319185)

  • 21. Two microbiological relapses in a patient with lepromatous leprosy.
    Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
    Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.
    Kumar A; Girdhar A; Girdhar BK
    Indian J Dermatol Venereol Leprol; 2015; 81(4):356-62. PubMed ID: 26144850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy trial in paucibacillary leprosy using clofazimine.
    Katoch K; Natarajan M; Katoch VM; Singh HB; Bhatia AS
    Indian J Lepr; 1999; 71(3):311-24. PubMed ID: 10626237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):436-44. PubMed ID: 1474282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An evaluation of clinical and histopathological status in paucibacillary leprosy patients after completion of fixed duration therapy.
    Mathew D; Kishore BN; Shwethadri GK; Sukumar ; Shetty NJ
    Indian J Lepr; 2004; 76(1):11-8. PubMed ID: 15527055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of multidrug therapy in paucibacillary leprosy.
    Kar PK; Sohi AS
    J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Problems of leprosy relapse in China.
    Li HY
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):1-7. PubMed ID: 8326169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
    Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
    J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse rate in paucibacillary leprosy patients after multidrug therapy in North Arcot District.
    Ekambaram V; Rao MK
    Indian J Lepr; 1991; 63(1):34-42. PubMed ID: 1919088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
    Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
    Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
    Biswas S; Mondal KK
    Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug therapy for treatment of paucibacillary leprosy in western Kenya--preliminary communications.
    Orege PA; Obura M; Okelo C; Okuku P; Makokha S; Nyawalo J
    East Afr Med J; 1990 Sep; 67(9):632-9. PubMed ID: 2253572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paucibacillary multidrug therapy in leprosy. 7 1/2 years experience.
    Kaur S; Sharma VK; Basak P; Kaur I
    Indian J Lepr; 1992; 64(2):153-61. PubMed ID: 1607713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
    Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
    Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
    Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.